Takeda Pharmaceutical Company Limited: Takeda's QDENGA? (Den

The European Commission Approved QDENGA (TAK-003) for Use in Individuals Four Years of Age and Olderi QDENGA Becomes the Only Dengue Vaccine Approved in the EU for Use in Individuals Regardless of Previous

Related Keywords

Indonesia , Sri Lanka , Japan , Philippines , United States , Brazil , Colombia , Nicaragua , Germany , Thailand , Siyambalapitiya , Sabaragamuwa , Dominican Republic , Bulugahapitiya , Central , Italy , Panama , Spain , France , Berlin , America , Japanese , Gary Dubin , Rachel Higgins , Tomas Jelinek , Jun Saito , European Commission , World Health Organization , International Media , Berlin Centre For , Data Monitoring Committee , Exchange Commission , European Commission Approved , European Union Eu Member States , European Union , Takeda Pharmaceutical Company Limited , European Centre For Disease Prevention , Individuals Four Years , Only Dengue Vaccine Approved , Individuals Regardless , Previous Dengue , Dengue Tetravalent Vaccine , European Medicines Agency , Medicinal Products , Human Use , Global Vaccine Business Unit , Medical Director , Berlin Centre , Tropical Medicine , Scientific Director , Dengue Efficacy Study , Fiscal Year , Member States , Tetravalent Immunization , Product Characteristics , Latin America , Rare Genetics , Plasma Derived Therapies , Annual Report , Retrieved December , World Health , European Centre , Disease Prevention , Imported Infectious Diseases , Clinical Features , Imported Dengue Fever , Sentinel Surveillance Data , Clin Inf , Tourism Statistics , Tetravalent Dengue Vaccine Candidate , Northern European Conference , Travel Medicine , Tetravalent Dengue Vaccine , Healthy Children , Takeda , Harmaceutical , Company , Imited , Udenga , Dengue , Etravalent , Vaccine , Five , Attenuated , Approved , European , Union ,